Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients
PHASE2CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
February 1, 2020
Primary Completion Date
July 30, 2021
Study Completion Date
July 30, 2021
Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG
CBD
300 mg CBD
Trial Locations (1)
Unknown
Meir Medical Center, Kfar Saba
All Listed Sponsors
lead
Stero Biotechs Ltd.
INDUSTRY
NCT04439955 - Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients | Biotech Hunter | Biotech Hunter